Polymicrobial Diseases
Polymicrobial Diseases

Edited by

Kim A. Brogden
Respiratory Diseases of Livestock Research Unit
National Animal Disease Center
Agricultural Research Service
U.S. Department of Agriculture
Ames, Iowa

Janet M. Guthmiller
Department of Periodontics
and Dows Institute for Dental Research
College of Dentistry
The University of Iowa
Iowa City, Iowa
CONTENTS

Contributors ix
Preface xiii

I INTRODUCTION 1

1. Polymicrobial Diseases of Animals and Humans
   Kim A. Brogden 3

2. Continuous-Culture Chemostat Systems and Flowcells
   as Methods To Investigate Microbial Interactions
   David R. Drake and Kim A. Brogden 21

II POLYVIRAL DISEASES 31

3. Bovine Viral Diarrhea Virus in Mixed Infections
   Steven R. Bolin 33

4. Infections with Multiple Hepatotropic Viruses
   Robert P. Myers, Vlad Ratziu, Yves Benhamou, Vincent Di Martino,
   Joseph Moussalli, Marie Hélène Tainturier, and Thierry Poynard 51

5. Concomitant Infections with Human Immunodeficiency
   Virus Type 1 and Human T-Lymphotropic Virus Types 1 and 2
   Abelardo Araujo, Noreen Sheehy, Hidehiro Takahashi, and William W. Hall 75

6. Viruses and Multiple Sclerosis
   Donatella Donati and Steven Jacobson 99
### III POLYBACTERIAL DISEASES 125

7. Bacterial Vaginosis as a Mixed Infection  
   *Phillip E. Hay*  
   127

8. Periodontal Diseases  
   *Janet M. Guthmiller and Karen F. Novak*  
   137

9. Abscesses  
   *Itzhak Brook*  
   153

10. Atrophic Rhinitis  
    *Tibor Magyar and Alistair J. Lax*  
    169

### IV POLYMICROBIAL DISEASES INVOLVING VIRUSES AND BACTERIA 199

11. Cooperation between Viral and Bacterial Pathogens in Causing Human Respiratory Disease  
    *Harry Smith and Clive Sweet*  
    201

12. Respiratory Viruses and Bacteria in Cattle  
    *Douglas C. Hodgins, Jennifer A. Conlon, and Patricia E. Shewen*  
    213

13. Porcine Respiratory Disease Complex  
    *Susan L. Brockmeier, Patrick G. Halbur, and Eileen L. Thacker*  
    231

14. Otitis Media  
    *Lauren O. Bakaletz*  
    259

15. Mixed Infections of Intestinal Viruses and Bacteria in Humans  
    *John A. Marshall*  
    299

16. Interactions between Herpesviruses and Bacteria in Human Periodontal Disease  
    *Jørgen Slots*  
    317

### V POLYMICROBIAL DISEASES INVOLVING FUNGI 333

17. Mixed Mycotic Infections  
    *David R. Soll*  
    335
18. Interactions between *Candida* Species and Bacteria in Mixed Infections
   Howard F. Jenkinson and L. Julia Douglas
   357

VI POLYMICROBIAL DISEASES AS A RESULT OF MICROBE-INDUCED IMMUNOSUPPRESSION 375

19. Virus-Induced Immunosuppression
   Jane E. Libbey and Robert S. Fujinami
   377

20. Human Immunodeficiency Virus, *Pneumocystis carinii*, *Toxoplasma gondii*, and *Leishmania* Species
    Raul E. Isturiz and Eduardo Gotuzzo
    389

VII CONCLUDING PERSPECTIVE 401

21. Polymicrobial Diseases: Current and Future Research
    Kim A. Brogden and Janet M. Guthmiller
    403

Index 411
CONTRIBUTORS

Abelardo Araujo
Centro de Pesquisa Hospital Evandro Changas, Ministerio da Saude, Av. Brasil, 4365, Manguinhos, Cep., Rio de Janeiro 21045-900, Brazil

Lauren O. Bakaletz
Division of Molecular Medicine, College of Medicine and Public Health, The Ohio State University, and Children’s Research Institute, Columbus, OH 43205

Yves Benhamou
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière, 75651 Paris, France

Steven R. Bolin
Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824

Susan L. Brockmeier
Respiratory Diseases of Livestock Research Unit, National Animal Disease Center, USDA Agricultural Research Service, Ames, IA 50010

Kim A. Brogden
Respiratory Diseases of Livestock Research Unit, National Animal Disease Center, USDA Agricultural Research Service, Ames, IA 50010

Itzhak Brook
Department of Pediatrics, Georgetown University School of Medicine, Washington, DC 20007

Jennifer A. Conlon
Biocor Animal Health, 2720 North 84th St., Omaha, NE 68134

Vincent Di Martino
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière, 75651 Paris, France
CONTRIBUTORS

Donatella Donati
Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, and Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Università di Siena, via Laterina 8, 53100 Siena, Italy

L. Julia Douglas
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom

David R. Drake
Dows Institute for Dental Research and Department of Endodontics, College of Dentistry, University of Iowa, Iowa City, IA 52242

Robert S. Fujinami
Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132

Eduardo Gotuzzo
Alexander von Humboldt Institute of Tropical Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

Janet M. Guthmiller
Department of Periodontics and Dows Institute for Dental Research, College of Dentistry, University of Iowa, Iowa City, IA 52242

Patrick G. Halbur
Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011

William W. Hall
Department of Medical Microbiology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland

Phillip E. Hay
Department of Genitourinary Medicine, St. George’s Hospital Medical School, Cranmer Terrace, London SW17 0QT, United Kingdom

Douglas C. Hodgins
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1, Canada

Raul E. Isturiz
Centro Medico de Caracas and Centro Medico Docente La Trinidad, Caracas, Venezuela

Steven Jacobson
Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892

Howard F. Jenkinson
Department of Oral and Dental Science, University of Bristol Dental School, Bristol BS1 2LY, United Kingdom

Alistair J. Lax
Oral Microbiology, Guy’s King’s and St Thomas’ Dental Institute, King’s College London, London SE1 9RT, United Kingdom
CONTRIBUTORS

Jane E. Libbey
Department of Neurology, University of Utah School of Medicine,
Salt Lake City, UT 84132

Tibor Magyar
Veterinary Medical Research Institute, Hungarian Academy of Sciences,
H-1143 Budapest, Hungary

John A. Marshall
Victorian Infectious Diseases Reference Laboratory, Locked Bag 815,
Carlton South, Victoria 3053, Australia

Joseph Moussalli
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière,
75651 Paris, France

Robert P. Myers
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière,
75651 Paris, France

Karen F. Novak
Center for Oral Health Research, Division of Periodontics, College of Dentistry,
University of Kentucky, Lexington, KY 40536

Thierry Poynard
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière,
75651 Paris, France

Vlad Ratziu
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière,
75651 Paris, France

Noreen Sheehy
Department of Medical Microbiology, Conway Institute of Biomolecular
and Biomedical Research, University College Dublin, Belfield,
Dublin 4, Ireland

Patricia E. Shewen
Department of Pathobiology, Ontario Veterinary College, University of Guelph,
Guelph, Ontario N1G 2W1, Canada

Jørgen Slots
School of Dentistry, MC 0641, University of Southern California,
Los Angeles, CA 90089-0641

Harry Smith
Medical School, University of Birmingham, Birmingham B15 2TT,
United Kingdom

David R. Soll
Department of the Biological Sciences, University of Iowa, Iowa City,
IA 52242

Clive Sweet
School of Biosciences, University of Birmingham, Birmingham B15 2TT,
United Kingdom
Marie Hélène Tainturier
Service d’Hépato-Gastroentérologie, Groupe Hospitalier, Hôpital Pitié-Salpêtrière, 75651 Paris, France

Hidehiro Takahashi
Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan

Eileen L. Thacker
Veterinary Medical Research Institute, Iowa State University, Ames, IA 50011
The veterinary, medical, and dental literature is filled with reports of diseases involving more than one etiologic agent. These have come to be known as polymicrobial diseases. Polymicrobial diseases in animals and humans are more common than generally realized, and many perceived “single-etiologic-agent diseases,” when examined closely, contain polymicrobial etiologies. These include respiratory diseases, gastroenteritis, conjunctivitis, keratitis, hepatitis, Lyme disease, multiple sclerosis, genital infections, intra-abdominal infections, and pertussis.

*Polymicrobial Diseases* is a collection of chapters from investigators researching a variety of diseases with multiple etiologies. These diseases can be categorized as those originating from polyviral infections, polybacterial infections, viral and bacterial infections, and polymicrobial mycotic infections, and those that result in immunosuppression. The book begins with a section on an integrated view of polymicrobial diseases in animals and humans, including a representative list of these diseases, the etiologic agents, and the underlying mechanisms of pathogenesis (chapter 1). Also included in this section is a chapter on the in vitro methods for the study of polymicrobial diseases (chapter 2). Section II contains information on polyviral infections in animals (chapter 3), infections with multiple hepatotropic viruses (chapter 4), multiple retroviral infections (chapter 5), and viruses associated with multiple sclerosis (chapter 6). Section III discusses polybacterial infections, including bacterial vaginosis (chapter 7), periodontal disease (chapter 8), abscesses (chapter 9), and atrophic rhinitis in swine (chapter 10). Section IV comprises polymicrobial diseases involving viruses and bacteria. These are infections seen in respiratory diseases in humans (chapter 11) and animals (chapters 12 and 13), otitis media (chapter 14), and intestinal disorders (chapter 15). The emerging role of viruses in periodontal disease is also discussed (chapter 16). Section V discusses polymicrobial infections involving fungi (chapter 17) and *Candida* interactions with bacterial biofilms (chapter 18). Section VI focuses on polymicrobial diseases that result
from microbe-induced immunosuppression (chapter 19), which often allows other microbes to become established (chapter 20). In conclusion, section VII summarizes the state of polymicrobial infections in animals and humans (chapter 21).

Polymicrobial infections share underlying mechanisms of pathogenesis, and these are presented in chapter 1. First, stress, physiologic abnormalities, and metabolic disease favor the colonization of multiple organisms. Second, alterations induced in the mucosa by one organism favor the colonization of others. Third, synergistic triggering of proinflammatory cytokines increases the severity of disease, reactivates latent infections, or favors the colonization of other microorganisms. Fourth, sharing of determinants among organisms allows activities that organisms do not possess individually. Finally, suppression of the immune system by one organism allows the colonization of others.

We hope that *Polymicrobial Diseases* will stimulate great interest and spur discussion among its readers and draw together investigators from various fields to assess the mechanisms underlying the pathogenesis of these complex infections. This book provides an overview of our current knowledge of mixed infections in both animals and humans, and we believe that it will serve as a useful reference in this area. The emphasis is on identifying polymicrobial diseases, understanding the complex etiology of these diseases, recognizing difficulties in establishing methods for their study, identifying mechanisms of disease pathogenesis, and assessing appropriate methods of treatment. In some instances, the mechanisms of disease are not well known; in others, the mechanisms of pathogenesis have been under intense investigation. Our intent is to present another edition of this book dealing with the specific mechanisms of polymicrobial infection, host response to infection, predisposition and/or risk factors for the diseases, and pathogenesis of polymicrobial disease.

KIM A. BROGDEN
JANET M. GUTHMILLER
INDEX

Note: Page numbers followed by “f” indicate figures; page numbers followed by “t” indicate tables.

Abscesses, 153–168
abdominal, 154–155, 155t–157t, 158
head and neck, 155, 155t–157t
microbiology of
vs. body site, 153–155, 154f, 154t–157t, 158
in clinical specimens, 159–161, 160f
encapsulation, 158–162, 160f, 162f
experimental, 161–162, 162f
normal flora, 153–154, 154f, 154t
synergy, 163–166, 163t, 164t, 165f, 166t
virulence factors, 158
pelvic, 155t–157t, 158
skin, 153–155, 154f, 154t
urogenital, 155t–157t, 158
Actin stress fiber formation, in Pasteurella multocida
toxin activation, 182–183
Actinobacillus, in periodontal disease, 139
Actinobacillus actinomycetemcomitans, in periodontal
disease, 137–139
adherence of, 140
herpesvirus interactions with, 317, 318, 320–321, 321t, 324
host defense interactions with, 140–142, 144
tissue penetration by, 141–142
treatment directed to, 145–146
Actinobacillus pleuropneumoniae, in porcine respiratory
disease complex, 233, 233t, 238, 239, 241, 244, 245, 248–249
Actinomyces, on oral cavity structures, 363
Actinomyces naeslundii
in biofilm formation, 363
Candida coaggregation with, 365, 365f
in periodontal disease, 140
Acute interstitial pneumonia, in cattle, 404
Acyclovir, for multiple sclerosis, 115
Adefovir, for hepatotropic viral coinfections, 64–65
Adenovirus (bovine), in bovine respiratory disease
complex, 219
Adenovirus (human)
in gastroenteritis, 301, 303, 303t, 305t
infection with
in measles virus infection, 379
viral-bacterial cooperation in, 202, 203t
in otitis media, 260–261, 262f
animal models of, 263–264, 265f
pathogenic mechanisms and, 266, 268, 271, 275–276, 278, 278f, 279f, Color Plate 2
treatment of, 286f–287f, 288
Adenovirus (ovine), 219
Adenovirus (porcine), in porcine respiratory disease
complex, 242
Adenylate cyclase toxin, in atrophic rhinitis,
176–178, 177f
Adherence
in atrophic rhinitis, 174, 176, 185–186
to oral cavity structures, 362–366, 362f, 364f, 365f
in otitis media, 266, 267f, 268, 269f
in periodontal diseases, 139–140
in porcine respiratory disease complex, 239
in viral-bacterial cooperation, 203–204, 203t, 204t
in viral-bacterial gastroenteritis, 308
Adult T-cell leukemia/lymphoma, in human
T-lymphotropic virus infection, 78–79
Aerococcus viridans infection, viral-bacterial
cooperation in, 207
Aeromonas, in gastroenteritis, 300, 302t, 303t, 305t
AG7088 (protease inhibitor), for otitis media, 284
AIDS, see Human immunodeficiency virus infection
Air pollutants, in atrophic rhinitis, 185
Alternaria, in mixed fungal infections, 346
Amoxicillin, for otitis media, 273
Amphotericin B
for leishmaniasis, 396
for oral Candida-bacterial infections, 368
α-Amylase, in biofilm formation, 362, 363
Anaerobic bacteria
in abscesses
vs. body site, 153–155, 154f, 154t–157t, 158
encapsulation of, 158–162, 160f, 162f
significance of, 162–163
synergy with aerobic bacteria, 163–166, 163t, 164t, 165f, 166t
virulence of, 158
in bacterial vaginosis, 128, 132
vs. body site, virulence of, 158
Candida inhibition by, 339
in periodontal disease, Candida with, 360
Anemia, Fanconi’s, periodontal disease in, herpesviruses in, 321, 322t
Angular cheilitis, Candida-bacteria interactions in, 399, Color Plate 6
Antibiotics
for atrophic rhinitis, 172–173
normal flora imbalance caused by, 339
for otitis media, 282–283
viral effects on, 271–274, 272t
for periodontal disease, 145–146
for porcine respiratory disease complex, 250–251
resistance to, in biofilms, 367–368, 407
Antigens
bovine viral diarrhea virus, 34–36
myelin, in multiple sclerosis, 102
in periodontal disease, 143–144
Antifungal agents, for oral Candida-bacterial infections, 368–369
Antigenic modulation
in atrophic rhinitis, 180–181, 181f
in swine influenza virus, 235–236
Antiinflammatory agents, for otitis media, 283
Antimonial salts, for leishmaniasis, 396
Apoptosis
of dendritic cells, in measles, 382
resistance to, in adult T-cell leukemia/lymphoma pathogenesis, 79
Apx toxins, in porcine respiratory disease complex, 241
Arcanobacterium pyogenes infection, bovine viral diarrhea virus infection with, 41
Aspergillus
in mixed fungal infections, 346, 347
in normal flora, 335
in periodontal disease, 360
Astroviruses, in gastroenteritis, 301, 304, 304t, 305t
Atherosclerosis, as polymicrobial disease, 404
Atrophic rhinitis (porcine), clinical features of, 170–171
economic importance of, 172
histopathology of, 172
historical background of, 169–170
organism interactions in, 185–187
pathology of, 171–172, 171f
prevention of, 173–174
treatment of, 172–173
vaccination for, 173–174
virulence factors in, 174–183
adhesion, 174, 176, 185–186
filamentous hemagglutinin, 175–176
fimbriae, 174–175
pertactin, 176
regulation of, 180–181, 181f, 183
toxins, 176–180, 177f, 182–187
type III secretion system for, 180
Aujeszky’s disease virus (pseudorabies virus), 237–238, 242, 244
Autoimmune disorders
multiple sclerosis, see Multiple sclerosis
postinfectious encephalomyelitis, 105–106
subacute sclerosing panencephalitis, 106
viruses inducing, 103–107, 113–114
B lymphocytes, measles virus interactions with, 380–381
Bacillus
in gastroenteritis, 300, 303t, 305t
infection with, bovine viral diarrhea virus infection with, 41
Bacillus thuringiensis infection, viral-bacterial cooperation in, 202
Bacteremia
from central venous catheter, 361
Haemophilus parasuis, 241–242
Salmonella suis, 242
Bacteria, see also specific bacteria and diseases
in polymicrobial diseases, 4, 5t
with fungi, 7t, 335–373
with parasites, 7t
polybacterial, see Polybacterial diseases
with viruses, see Virus(es), in polymicrobial diseases, with bacteria
Bacterial vaginosis, 127–135
candidiasis with, 346
complications of, 128–129, 133
diagnosis of, 128, 128t
epidemiology of, 129–131, 130f
microbiology of, 131–133
natural history of, 129–130, 130f
in pregnancy, 130, 133
prevalence of, 127–128
risk factors for, 131
smoking and, 405
treatment of, 128–129, 129t
vaginal physiology and, 128
INDEX

Bacteroides
in bacterial vaginosis, 131–132
in periodontal disease, 139–142
Candida
interactions with, 360
herpesvirus interactions with, 318, 323, 323t
in vagina, 338t
Bacteroides fragilis,
in abscesses, 154–155, 157t, 158–161, 160f, 162f, 163–164, 164t, 165f, 166
Bacteroides thetaiotaomicron,
host response to, 406–407
Biofilms
antibiotic resistance in, 407
on catheters, 361
diseases related to, 406
on oral cavity structures, 362–368, 362f, 364f–366f
adhesion mechanisms in, 363–364
colonization in, 362–363, 362f
mixed communities in, 365–368, 364f, 365f
properties of, 366–367, 366f
in otitis media, 281, 283, Color Plate 2, Color Plate 3
in periodontal disease, 137–139, 143, 145, Color Plate 1
for polymicrobial disease studies
in continuous–culture chemostat systems, 22–25, 23f, 24t
in flowcells, 24t, 26–28, 27f
on prostheses, 360–361, 361f, 369
structure of, Color Plate 3
Blood, human T-lymphotropic virus transmission through, 77
Blood-brain barrier, breakdown of, in multiple sclerosis, 101
Bone
deformities of, in atrophic rhinitis, 170–172, 171f, 183–185
loss of, in periodontal disease, 142–144
Bordetella bronchiseptica
in atrophic rhinitis, see Atrophic rhinitis
Bordetella pertussis
adenylate cyclase toxin of, 176
filamentous hemagglutinin of, 175
host response to, 407
infection with, viral-bacterial cooperation in, 202, 203t
toxins of, in viral–bacterial cooperation, 206, 250
Bovine adenovirus, in bovine respiratory disease complex, 219
Bovine coronavirus, in bovine respiratory disease complex, 219–220
Bovine herpesvirus 1 infection, bovine viral diarrhea virus infection with, 41, 214–216
Bovine respiratory disease complex, 213–229
bacteria associated with, 214, 220–222
risk factors for, 214
treatment of, 213
undifferentiated, 213
vaccination for, 213
viruses associated with, 213–220
bovine adenovirus, 219
bovine coronavirus, 219–220
bovine herpesvirus type 1, 214–216
bovine respiratory syncytial virus, 217–218
bovine viral diarrhea virus, 39–41, 218–219
parainfluenza virus 3, 216–217
Bovine respiratory syncytial virus
in bovine respiratory disease complex, 217–218
infection, bovine viral diarrhea virus infection with, 41
Bovine rotavirus infection, bovine viral diarrhea virus infection with, 41
Bovine viral diarrhea virus, 33–50
acute infection with, 33–34, 39–41
antibodies to, 34–36
in bovine respiratory disease complex, 218–219
congenital persistent infection with, 33–35
cytopathic
mixed infection with, 35–36, 36f
vs. noncytopathic, 33, 219
origin of, 36–38, 37t
in enteric disease, 41
genomic organization of, 36, 36f
immunotolerance to, 34–35
microbiology of, 33
in mucosal disease, 33–39
clinical features of, 34
congenital persistent, 34–35
mixed infection in, 35–36, 36f
pathogenesis of, 38–39
viral origin in, 36–38, 37t
noncytopathic
congenital persistent infection with, 34–35
vs. cytopathic, 33, 219
cytopathic virus development from, 36–38, 37t
pathogenic mechanisms of, 38–41
replication of, 33–34
in reproductive disease, 41–42
in respiratory disease, 39–41, 218–219
transmission of, 34–35, 38
vaccination for, 38
Bronchus-associated lymphoid tissue, bovine viral diarrhea virus infection of, 40
Bud-hypha transition, in phenotypic switching, 350, 350f
BVDV, see Bovine viral diarrhea virus
bvg virulence gene, of Bordetella bronchiseptica, 180–181, 181f, 240
Bystander effects, in virally induced demyelination, 103
C protein, of measles virus, 379
Calculus (plaque)
formation of, 362–364
in periodontal disease, 137–139, 143, 145, Color Plate 1
Caliciviruses
in gastroenteritis, 301
hepatitis E virus, 53
Calmodulin
in adenylate cyclase toxin activation, 176–177, 177f
in *Pasteurella multocida* toxin activation, 182
*Campylobacter*
in gastroenteritis, 300, 302t–305t, 303–305
in vitro studies of, 309–310
in periodontal disease, 139, 141
*Campylobacter fetus* infection, bovine viral diarrhea virus infection with, 41
*Campylobacter rectus*
dental implant colonization by, 360
in periodontal disease, herpesvirus interactions with, 318
Cancer risk, in hepatitis B virus-hepatitis C virus coinfection, 56
*Candida*
 antibiotic resistance of, in biofilms, 367
bacterial interactions with, 335, 338–340, 338t, 339f, 346, 357–373
adhesion mechanisms in, 363–364
in angular cheilitis, 359, Color Plate 6
in biofilms, 366–368, 366f
colonization, 362–368, 362f, 364f–366f
community development in, 365–366, 364f, 365f
in denture-induced stomatitis, 359, Color Plate 6
in gingivitis, 359–360
host perturbations and, 369–370, 369f
management of, 368–369
in periodontal disease, 360
in prosthetic implants, 360–361, 361f, 369
in bacterial vaginosis, 129–130, 130f
body distribution of, 336–338, 337t, 357
characteristics of, 357–358
colonization by, *see* Colonization, of *Candida*
infected tissues with, predisposing factors for, 358–359
in mixed infections
bacteria with, *see* Candida, bacterial interactions with
commensalism and, 336–338, 337t
multiple *Candida* species in, 340–341, 341t, Color Plate 5
multiple *Candida* strains and substrains in, 341–345, 342f, 343t, 344f
other fungal species with, 346–348, 349f
phenotypic heterogeneity in, 348, 350–352, 350f, 351f
recurrent, 345–346
mucoctaneous, 358
nosocomial acquisition of, 358–361, 361f
in superficial infections, 358
in systemic infections, 358
on vascular catheters, 361
*Capnocytophaga*, in periodontal disease, 139, 144, 405
Capsule, of microorganisms, in abscesses, 158–162, 160f, 162f
Carriage, *see* Colonization; Normal flora
Catheters, *Candida* on, 358–359, 361
Cattle
bovine respiratory disease complex in, 213–229
bovine viral diarrhea virus affecting, *see* Bovine viral diarrhea virus
gastroenteritis in, mixed viral-bacterial, 307
new diseases of, 403–404
CD46, in measles virus-induced immunosuppression, 381, 382
Cell-mediated immunity, in measles virus infection, 380
Central nervous system, multiple sclerosis of, *see* Multiple sclerosis
Central venous catheter, microbial colonization of, 361
Cheilitis, angular, *Candida*-bacteria interactions in, 399, Color Plate 6
Chemokines
in HIV–HTLV coinfections, 85–86
in HIV infection, 390
in periodontal disease, 324
Chemostat, for continuous culture, of polymicrobial systems, 22–25, 23f, 24t
*Chlamydia*
in bovine respiratory disease complex, 214
infection with, in measles virus infection, 379
in porcine respiratory disease complex, 233
Cholera, 300, 302t, 305–306
CHROMagar, for *Candida* culture, 340–341, 341t, Color Plate 5
Ciliary transport, viral effects on, in otitis media, 275–280, 276f–279f, 277t, Color Plate 2
Cirrhosis
in hepatitis B virus-hepatitis C virus coinfection, 56
in hepatitis B virus-hepatitis D virus coinfection, 57
in HIV–hepatitis C virus coinfection, 60–61
*Citrobacter*, in vagina, 338, 338t
Clindamycin, for bacterial vaginosis, 129t
*Clostridium*
in abscesses, 157t, 158, 160–163, 164t, 166, 166t
in gastroenteritis, 300, 302t, 304t, 305t
Clotrimazole, for bacterial vaginosis, 130f
Clue cells, in bacterial vaginosis, 128
Clumping factor, in viral-bacterial cooperation, 204
Coaggregation, of *Candida* with other microbes, 364f, 365, 365f

Colonization
- in atrophic rhinitis, 185–187
- in bovine respiratory disease complex, 214, 221 of *Candida*, 336–338, 337t
  - with multiple species, 340–341, 341t, Color Plate 5
  - with multiple strains and substrains, 341–345, 342f, 343t, 344f
- on prostheses, 360–361, 361f, 369
- of oral cavity structures, 362–368, 362f, 364f–366f
- in otitis media, 266, 267f, 268, 269f
- in periodontal diseases, 139–140, 324
- in polymicrobial diseases, 8–10

Commensalism, see *Normal flora*

Complement
- activation of
  - in measles, 381
  - in multiple sclerosis, 101–102, 114
  - in otitis media, 280
- interference with, in viral-bacterial cooperation, 205

Complex probes, for *Candida* fingerprinting, 342–343, 342f, 343t, 344f, 345

Contact hypersensitivity response, measles virus effects on, 382

Continuous-culture chemostat systems, for polymicrobial disease studies, 22–25, 23f, 24t

Copolymer-1, for multiple sclerosis, 115

Coronavirus (bovine), in bovine respiratory disease complex, 219–220

Coronavirus (human)
- in gastroenteritis, 301
- in otitis media, 261

Coronavirus (porcine)
- bacterial interactions with, 220
- in gastroenteritis, 306–307
- in porcine respiratory disease complex, 237, 244–245, 247–248

Cows, see *Cattle*

*Coxiella burnetii* infection, bovine viral diarrhea virus infection with, 41

Coxsackie viruses, in gastroenteritis, in vitro studies of, 308–310

αB-Crystallin, in multiple sclerosis pathogenesis, 114

Culture, of polymicrobial systems
- batch, 21–22
- continuous-culture chemostat systems for, 22–25, 23f, 24t

Cyclic AMP, in adenylate cyclase toxin activation, 177, 177f

Cytokines
- in bovine respiratory disease complex, 216
- in human T-cell leukemia virus type 1-associated myelopathy, 107
- in measles virus-induced immunosuppression, 380–383
- in multiple sclerosis, 101–102, 115
- in otitis media, 273–274, 280
- in periodontal disease, 144, 324
- in polymicrobial infection, 9–10
- in porcine respiratory disease complex, 239, 241, 247
- in *Toxoplasma gondii* infection, 394
- in viral-bacterial cooperation, 206

Cytolethal distending toxin, of *Actinomyces actinomycetemcomitans*, in periodontal diseases, 140–141

Cytomegalovirus (human)
- characteristics of, 319–320
- in gastroenteritis, 301
- infection with, viral-bacterial cooperation in, 202
- in periodontal disease, 317, 318, 320–323, 320t–323t
- host response to, 325–326
- pathogenic mechanisms in, 324–325
- PCR detection of, 320

Cytomegalovirus (porcine), in porcine respiratory disease complex, 242

Dapsone-pyrimethamine, for toxoplasmosis, 395

Deacetylases, in fungal phenotype switching, 351

Debridement, for periodontal disease, 145–146

Defensins, in periodontal disease, 143

Delayed-type hypersensitivity test, measles virus effects on, 379, 382

Demyelination
- in multiple sclerosis, see *Multiple sclerosis* viruses inducing, 103–107

Dendritic cells, measles virus interactions with, 381–383

Dendrograms, in *Candida* fingerprinting, 342–343, 342f, 344f, 345

Dendrites, measles virus interactions with, 381–383

Dendrites, in *Candida* fingerprinting, 342–343, 342f, 344f, 345

Dental implants, *Candida*-bacterial colonization of, 360

Dental plaque
- formation of, 362–364
- in periodontal disease, 137–139, 143, 145, Color Plate 1

Dentures
- *Candida*-bacterial infections related to, 359, Color Plate 6
- *Candida* colonization of, 359, 368
- cleaning of, 368

Dermonecrotic toxin
- in atrophic rhinitis, 177f, 178–179, 184, 186–187
- in porcine respiratory disease complex, 240–241, 250

*Desulfovibrio ovale*, in periodontal disease, 405

*Dialister pneumosintes*, in periodontal disease, 405

Herpesvirus interactions with, 317, 318, 320, 320t, 323

Diabetes, in bovine viral diarrhea virus infection, 34
Diphtheria, see *Bordetella pertussis*

DNA analysis, of mixed *Candida* strains and substrains, 342–343, 342f, 343t, 344f, 345

Douching, bacterial vaginosis and, 129

Drug abuse, intravenous, human T-lymphotropic virus transmission during, 75–77

Ear, middle, inflammation of, see *Otitis media*

Echoviruses, in gastroenteritis, in vitro studies of, 309

Economic issues
  in atrophic rhinitis, 172
  in *otitis media*, 259

*Eikenella*, in periodontal disease, 139–141, 144

Elderly persons, mixed fungal carriage in, 341, 341t

Electrophoresis, multilocus enzyme, for *Candida* fingerprinting, 342

Encapsulation, of microorganisms, in abscesses, 158–162, 160t, 162f

Encephalitis, *Toxoplasma gondii*, in human immunodeficiency virus infection, 394

Encephalomyocarditis virus, in porcine respiratory disease complex, 242

Endotoxin, see *Lipopolysaccharide*

Enteric infections, mixed, bovine viral diarrhea virus in, 41

*Enterobacteria*
  in abscesses, 156t
  infection with, viral-bacterial cooperation in, 206
  in *vagina*, 338, 338t

*Enterobacteriaceae*, in abscesses, 155, 156t

*Enterococci*
  in abscesses, 156t, 161, 165f
  on vascular catheters, 361
  on voice prosthesis, 361

Enterotoxins, staphylococcal, in viral-bacterial cooperation, 206

*Enteroviruses*
  in gastroenteritis, in vitro studies of, 309
  in *otitis media*, 261

Enzyme-linked immunosorbent assay, for human immunodeficiency virus, 391

Epitope spreading, in virally induced demyelination, 103

Epstein-Barr virus
  characteristics of, 319–320
  in multiple sclerosis pathogenesis, 111, 113, 114
  in periodontal disease, 317, 318, 320–321, 320t–323t, 323
  host response to, 325–326
  pathogenic mechanisms in, 324–325
  PCR detection of, 320

Erythromycin, for *otitis media*, 282

*Escherichia coli*
  in abscesses, 156t, 160–161, 163, 163t, 165f, 166t
  dental implant colonization by, 360

in gastroenteritis, 299, 302t–305t, 303–305
  animal models of, 306–308
  in vitro studies of, 310
  in periodontal disease, 360
  in stomatitis, *Candida* with, 359
  in *vagina*, 338t

Estriol, for bacterial vaginosis, 133

*Eubacterium*
  in abscesses, 157t
  in periodontal disease, 139
  herpesvirus interactions with, 318

Eustachian tubes, viral compromise of, *otitis media* and, 269–271, 269f, 270f, 272f, 275–279, 276f–279f, 277t, Color Plate 2

Exfoliative erythroderma, in human immunodeficiency virus–human T-lymphotropic virus type 2 coinfection, 81–82

Experimental autoimmune encephalomyelitis, as multiple sclerosis model, 102–103

Facultative gram-positive cocci, in abscesses, 161–164, 163t, 166t

Famotic anemia, periodontal disease in, herpesviruses in, 321, 322t

Fc receptors, coronavirus binding to, in bovine respiratory disease complex, 220

Fetus, bovine viral diarrhea virus infection of, 33, 35, 41–42

Fibrinogen, in viral-bacterial cooperation, 204–205

FIlamentous hemagglutinin, of *Bordetella bronchiseptica*, 175–176, 186

Fimbrilae, of *Bordetella bronchiseptica*, 174–175

Fimbrillin, in dental plaque development, 140

Flowcells, for polymicrobial disease studies, 24t, 26–28, 27f

Fluconazole, for oral *Candida*-bacterial infections, 368

Flucytosine, for *otitis media*, 283

Food poisoning, bacteria causing, 299–300

Fungi, see also specific fungi, e.g., *Candida*
  in polymicrobial diseases with bacteria, 357–373
  mixed mycotic infections, see Mixed mycotic infections

Fusidic acid, for oral *Candida*-bacterial infections, 368

Fusion protein, of measles virus, 378, 378f

*Fusobacterium*
  in abscesses, 155, 157t, 158–159, 161–163, 164t, 166
  in bacterial vaginosis, 131
  *Candida* coaggregation with, 365, 365f
  in mixed fungal infections, 346
  in periodontal disease
    *Candida* interactions with, 359, 360
    herpesvirus interactions with, 318

*Fusobacterium nucleatum*
  in dental plaque, 138
  in periodontal disease, 139–142, 144
G proteins
in adenylate cyclase toxin activation, 177, 177f
in Pasteurella multocida toxin activation, 182–183
Gardnerella vaginalis, in bacterial vaginosis, 128–133
Gastroenteritis, 299–316
bacterial, 299–300
mixed viral-bacterial
animal models of, 306–308
in asymptomatic individuals, 304–305, 305t
clinical features of, 305–306
incidence of, 301, 302t–304t, 303–304
in vitro studies of, 308–311
mechanisms of, 302–311, 305t
viral, 300–301
Gastrointestinal tract
Candida carriage in, 337, 337t
normal flora of, 153–155
Gene therapy, for histatin expression, in Candida infections, 369
Genetic factors
in multiple sclerosis, 107–108
in periodontal disease, 144–145
Gingipains, in periodontal disease, 142
Gingivitis, see also Periodontal diseases
acute necrotizing ulcerative, 322, 322t
definition of, 317
fungal-bacterial interactions in, 359–360
in periodontal disease, Color Plate 1
Glasser’s disease, 241–242
Glatiramer acetate, for multiple sclerosis, 115
Glycocalyx, in abscesses, 158
Glycoproteins
of measles virus, 378, 378f, 383
salivary, in biofilm formation, 362, 362f, 363
in viral-bacterial cooperation, 204
Gram-negative bacilli, in abscesses, 153, 160–162, 164
Gram-positive cocci, in abscesses, 154, 160
facultative, 161–164, 163t, 166t
Gut-associated lymphoid tissue, bovine viral diarrhea virus infection of, 39
HAART, see Highly active antiretroviral therapy
Haemophilus, in abscesses, 156t, 161, 163–164, 166t
Haemophilus influenzae
infection with
in measles virus infection, 379
viral-bacterial cooperation in, 201, 203, 203t, 204t, 205, 219
in otitis media, 260–261
animal models of, 263–265, 265f
pathogenic mechanisms and, 266, 267f, 268, 269f, 271, 279–280, Color Plate 2, Color Plate 4
treatment of, 282, 286f–287f, 288
Haemophilus parasuis, in porcine respiratory disease complex, 235, 238, 240–242, 244, 246, 249
Haemophilus somnus, in bovine respiratory disease complex, 221
Haemophilus vaginalis, see Gardnerella vaginalis
Hairy cell leukemia, in human immunodeficiency virus–human T-lymphotropic virus type 2 coinfection, 81
HAV infection, see Hepatitis A virus infection
HBV infection, see Hepatitis B virus infection
HCV infection, see Hepatitis C virus infection
Hda1 (deacetylase), in fungal phenotype switching, 351
HDV infection, see Hepatitis D virus infection
Heat-labile toxin (dennecrotic toxin)
in atrophic rhinitis, 177f, 178–179, 184, 186–187
in porcine respiratory disease complex, 240–241, 250
Hemagglutinating encephalomyocarditis virus, in porcine respiratory disease complex, 242
Hemagglutinin
of Bordetella bronchiseptica, 175–176, 186
of influenza virus, 206–207
of measles virus, 378, 378f
of swine influenza virus, 235–236
Hepatitis, non-A, non-B, see Hepatitis C virus infection
Hepatitis A virus infection, 52
epidemiology of, 51
HBV infection with, 59
HCV infection with, 59
Hepatitis B virus infection, 52
epidemiology of, 51
HAV infection with, 59
HCV-HDV infection with, 57–58, 63
HCV infection with, 54–56, 62–63
HDV infection with, 56–57, 63
HGV infection with, 58
HV infection with, 59–62, 64–65
Hepatitis C virus infection, 52–53
epidemiology of, 51
HAV infection with, 59
HBV-HCV infection with, 57–58, 63
HBV infection with, 54–56, 62–63
HGV infection with, 58
HV infection with, 59–61, 63–64
Hepatitis D virus infection, 51, 53
HBV–HCV infection with, 57–58, 63
HBV infection with, 56–57, 63
Hepatitis E virus infection, 53
Hepatitis G virus infection, 53–54
HBV or HCV infection with, 58
Hepatocellular carcinoma risk, in hepatitis B virus-hepatitis C virus co-infection, 56
Hepatotropic virus infections, 51–73
coinfections
HAV–HBV or HAV–HCV, 59
HBV–HCV, 54–56, 62–63
HBV–HCV–HDV, 57–58, 63
Hepatotropic virus infections (continued)
HBV–HDV, 56–57, 63
HGV–HBV or HGV–HCV, 58
HIV–HBV, 59–62, 64–65
HIV–HCV, 59–61, 63–64
transmission of, 62–65
epidemiology of, 51
etiologic agents of, 52–54
Herpes simplex virus
infection with, in measles virus infection, 379–380
in periodontal disease, 317, 318
Herpesviruses (bovine), in bovine respiratory disease complex, 214–216
Herpesviruses (human), see also specific herpesviruses
characteristics of, 318–320
in gastroenteritis, 301
infection with, viral–bacterial cooperation in, 205
in multiple sclerosis pathogenesis, 109–111, 113, 114
in periodontal diseases, see Periodontal diseases, herpesvirus–bacterium interactions in
HERV-W virus family, 112
HEV infection, see Hepatitis E virus infection
HGV infection, see Hepatitis G virus infection
Highly active antiretroviral therapy, for human immunodeficiency virus infection, 391, 393–394
viral hepatitis and, 59–60, 62
Histamine, in otitis media pathogenesis, 274–275
Histatins, as Candida defense, 368–369
HIV infection, see Human immunodeficiency virus infection
Hogs, see Pigs
Horses, gastroenteritis in, mixed viral–bacterial, 308
Host defenses
in bovine respiratory disease complex, 215
against herpesviruses, 319–320
against Leishmania, 396
in measles virus infection, 379–383
in otitis media, viral effects on, 274–275
pathogen interactions with, in periodontal diseases, 140–144, 325–326, 326f
of pig, 243, 243f
against Pneumocystis carinii, 392
in polymicrobial diseases, vs. individual infections, 406
in porcine respiratory disease complex, 239, 244, 249
against respiratory syncytial virus, 217–218
against swine influenza virus, 236
against Toxoplasma gondii, 394
viral–bacterial cooperation effects on, 205–206
HTLV-1 infection, see Human T-lymphotropic virus type 1 infection
HTLV-2 infection, see Human T-lymphotropic virus type 2 infection
Human herpesvirus 6, in periodontal disease, 317, 318
Human herpesvirus 7, in periodontal disease, 317, 318
Human herpesvirus 8
characteristics of, 319
in periodontal disease, 317, 318, 323, 327
Human immunodeficiency virus infection, 389–400
candidiasis in, 358
cytomegalovirus infections in, 319
epidemiology of, 75, 389, 390t
natural history of, 390–391
pathophysiology of, 390
periodontal disease in, 360
viral–bacterial cooperation in, 205
herpesviruses in, 317, 318, 322–323
Pneumocystis carinii infection in, 392–393
polymicrobial disease in, 10, 12
Toxoplasma gondii infection in, 393–395
transmission of, 75, 389, 133
treatment of, 391–392
type 1 vs. type 2, 75
viral–bacterial cooperation in, 205
Human leukocyte antigens, in multiple sclerosis, 108
Human T-lymphotropic virus type 1 infection
epidemiology of, 75–78
HIV infection with
HIV influence on, 78–81
HIV progression in, 83–86
HTLV-2 infection with
HIV influence on, 81–83
HIV progression in, 83–86
Leishmania infection in, 395–396
mixed fungal infections in, 346–347
natural history of, 390–391
pathophysiology of, 390
periodontal disease in, 360
HIV influence on, 78–81
HIV progression in, 83–86
myelopathy/tropical spastic paraparesis in, 12, 79–80, 82, 84, 107, 112
transmission of, 75–78
Human T-lymphotropic virus type 2 infection
epidemiology of, 75–78
HIV infection with
HIV influence on, 81–83
HIV progression in, 83–86
immunosuppression in, 83
subtypes of, 76
transmission of, 75–78
Humoral immunity, see also T lymphocytes
in measles virus infection, 380
Hwp1 (hypha-specific protein), in Candida adhesion, 363–364
Hydrogen peroxide, lactobacilli producing, 132–133
Hypha-specific protein Hwp1, in Candida adhesion, 363–364
Immune globulin
for measles, 380, 383
respiratory syncytial virus, for otitis media, 285
Immune response, see Host defenses
Immunization, see Vaccination
Immunoglobulin(s)
oligoclonal band patterns of, in multiple sclerosis, 102
polyclonal, for multiple sclerosis, 115
Immunoglobulin A, in biofilm formation, 362, 363
Immunosuppression, see also Human immunodeficiency virus infection
candidiasis in, angular cheilitis, 359, Color Plate 6
in HTLV infections, 78
measles virus in, 379–383
mixed fungal infections in, 346–347
periodontal disease in, 360
herpesvirus involvement in, 318, 322–323, 322t, 325
polymicrobial diseases in, 11–12
Immunotolerance, to bovine viral diarrhea virus, 34–36
Implants, Candida on, 358–361, 361f
In vitro models, for polymicrobial diseases, 21–30
batch culture, 21–22
continuous-culture chemostat systems, 22–25, 23f, 24t
flowcells, 24t, 26–28, 27f
Infants, human T-lymphotropic virus vertical transmission to, 76–77
Infectious mononucleosis, 319
in multiple sclerosis pathogenesis, 111, 113, 114
Influenza virus (human)
infection with
bacterial infections with, observations of natural disease in, 201–202
viral-bacterial cooperation in
bacterial protease in, 206–207
evidence of, 202–203
host defense inhibition and damage in, 205–206
mechanisms of, 203–207, 203t, 204t
mucous surface infection in, 203–205, 203t, 204t
tissue penetration and growth in, 205
in otitis media, 260–261, 262f
animal models of, 263–264, 264f
pathogenic mechanisms and, 266, 268, 270–271, 270f, 273–275, 276f, 277f, 277t, 279
treatment of, 284, 284t–285t
vaccination for, 284–285, 284t, 285t
Influenza virus (swine), in porcine respiratory disease complex, 233, 233t, 235–237, 245, 247–248
Interferon(s)
alpha
for adult T-cell leukemia/lymphoma, 79
for hepatotropic viral coinfections, 62–65
in porcine respiratory disease complex, 247–248
synthesis of, in bovine respiratory disease complex, 220
beta, for multiple sclerosis, 115
for measles treatment, 383
in measles virus-induced immunosuppression, 380–383
in multiple sclerosis pathogenesis, 101–102
in Toxoplasma gondii response, 394
Interleukin(s)
in adult T-cell leukemia/lymphoma, 78–79
in bovine respiratory disease complex, 220
in measles virus-induced immunosuppression, 380–383
in multiple sclerosis, 101–102
in otitis media, 273–274
in periodontal disease, 114, 324
in polymicrobial infection pathogenesis, 9–10
in porcine respiratory disease complex, 247–248
in Toxoplasma gondii response, 394
Invasion paradigm, of viral-bacterial gastroenteritis, 308
Itraconazole, for oral Candida-bacterial infections, 368
JC virus infection, progressive multifocal leukoencephalopathy in, 106–107
JHM strain of Theiler’s murine encephalomyelitis virus, 104–105
Kaposi’s sarcoma-associated virus, see Human herpesvirus 8
Klebsiella pneumoniae
in abscesses, 156t, 161–164, 163t, 165f
in otitis media, 280
L (large) protein, of measles virus, 378–379, 378f
Lactobacilli
for Candida infection treatment, 369
Candida interactions with, 339
vaginal
in bacterial vaginosis, 128, 132–133
factors reducing, 131
normal levels of, 128
phages killing, 131
substances produced by, 132–133
Lamivudine
for hepatotropic virus coinfections, 64–65
for HIV–HTLV-2 coinfection, 83
for HTLV infection, 80
Laryngectomy prosthesis, Candida-bacterial infection of, 360–361, 361f, 369
Legionella pneumophila, in mixed infections, 346
Leishmania infection, in human immunodeficiency virus infection, 395–396
Leptospira borgpetersenii serovar hardjo, bovine viral diarrhea virus coinfection with, 41
Leukemia
adult T-cell, in HTLV infection, 78–79
hairy cell, in HIV–HTLV-2 coinfection, 81
Leukotoxin
of *Actinomyces actinomycetemcomitans*, in periodontal diseases, 140
of *Mannheimia haemolytica*, in bovine respiratory disease complex, 221
Leukotrienes, in otitis media pathogenesis, 273–274
Lip, angular cheilitis of, *Candida*-bacterium interactions in, 399, Color Plate 6
Lipooligosaccharide
of *Haemophilus somnus*, in bovine respiratory disease complex, 221
in otitis media, 280
Lipopolysaccharide
in otitis media, 280
in porcine respiratory disease complex, 241
of *Porphyromonas gingivalis*, in periodontal disease, 141
in viral-bacterial cooperation, 206
*Listeria*, in gastroenteritis, 300, 310
*Listeria monocytogenes* infection, viral-bacterial cooperation in, 202
Liver, hepatotropic virus infections of, see Hepatotropic virus infections
Lymphocytes, depression of, in bovine respiratory disease complex, 216–217
Lymphoma, adult T-cell, in human T-lymphotropic virus infection, 78–79
Lymphoproliferative defect, in in vitro measles virus immunosuppression studies, 382
Lymphoproliferative disorders, in human immunodeficiency virus–human T-lymphotropic virus type 2 coinfection, 81–82
Macrophages, dysfunction of
in bovine respiratory disease complex, 215–217
in bovine viral diarrhea virus infection, 38–40
in HIV infection, 392
in otitis media, 274
in periodontal disease, 324
in porcine respiratory disease complex, 234–235, 244, 246–247
in viral-bacterial cooperation, 205
*MAD1* protein, in adult T-cell leukemia/lymphoma pathogenesis, 78
Magnetic resonance imaging, for toxoplasmosis, 394
Major histocompatibility complex antigens, in multiple sclerosis, 108
*Mannheimia haemolytica*
in bovine respiratory disease complex, 215, 217–221
infection with, bovine viral diarrhea virus infection with, 41
Mastoiditis, in otitis media, 282–283
Matrix metalloproteinases, in periodontal disease pathogenesis, 144
Matrix protein, of measles virus, 379
Measles virus, 377–387
bacterial cooperation with, observations of natural disease in, 202
characteristics of, 378–379, 378f
in gastroenteritis, in vitro studies of, 309
history of, 377–378
immunosuppression induced by, 379–383
immunologic paradox in, 379–380
models for, 380–383, 380t
treatment of, 383
multiple sclerosis and, 109, 113, 114
postinfectious encephalomyelitis and, 105–106
subacute sclerosing panencephalitis and, 106
vaccination for, 378, 383
Menstrual cycle, vaginal flora changes during, 128–130, 130f
Metabolic disease, polymicrobial diseases in, 9
Metalloproteinases, in periodontal disease pathogenesis, 144
Metronidazole
for bacterial vaginosis, 129–130, 129t, 130f
for oral *Candida*-bacterial infections, 368
Miconazole, for oral *Candida*-bacterial infections, 368
MIPs, in human immunodeficiency virus–human T-lymphotropic virus coinfections, 85–86
Mitogenic activity
of *Mycoplasma*, in bovine respiratory disease complex, 222
of *Pasteurella multocida* toxin, 184
Mixed mycotic infections, 335–356
*Candida* and bacteria, 338–340, 338t, 339f
commensalism and, 335–338, 337t
fungal-bacterial, 346
genetic relatedness in, 336, 336f
multiple *Candida* species in, 340–341, 341t, Color Plate 5
multiple *Candida* strains and substrains in, 341–345, 342f, 343t, 344f
multiple fungal species in, 346–347
multiple fungal strains and substrains in, 347–348, 349f
phenotype heterogeneity in, 348, 350–352, 350f, 351f
recurrent *Candida*, 345–346
types of, 335–336, 336f
MLEE, see Multilocus enzyme electrophoresis
*Mobiluncus*, in bacterial vaginosis, 131–132
Molecular mimicry, in virally induced demyelination, 103
Mononucleosis, infectious, 319
in multiple sclerosis and, 111, 113, 114
*Moraxella catarrhalis*
in abscesses, 156t
in otitis media, 261, 265–266, 268, 269f, 280–281
Morbilivirus family, immunosuppression induced by, 378
Mouse hepatitis virus infection, demyelination in, 104
MS, see Multiple sclerosis
Mucins, salivary, in biofilm formation, 362, 363
Mucocutaneous candidiasis, 358
Mucosal infection
bovine viral diarrhea virus, 33–39
combined viral and bacterial, 203–205, 203t, 204t
Mucus, viral effects on, in otitis media, 275–280, 276f–279f, 277t, Color Plate 2
Multilocus enzyme electrophoresis, for *Candida* fingerprinting, 342
Multiple sclerosis, 99–124
animal models of, 102–105
clinical features of, 99–100
environmental factors in, 107–108
epidemiology of, 107–108
genetic factors in, 107–108
human models of virus-induced demyelination and, 105–107
natural history of, 100
neuropathology of, 100–101
pathogenesis of, 101–102
relapse in, 100
treatment of, 115
viruses associated with, 108–113
autoimmunity and, 113–114
Epstein–Barr virus, 111, 113, 114
herpes simplex virus type 1, 111, 113
human herpesvirus 6, 109–111, 113, 114
measles virus, 109, 113, 114
multiple, 112–113
retroviruses, 112, 113
varicella-zoster virus, 111–112
Multiple sclerosis-associated retrovirus, 112
Mutualistic interactions, see Synergism
*Mycoplasma*, in bovine respiratory disease complex, 221–222
*Mycoplasma hominis*, in bacterial vaginosis, 131–132
*Mycoplasma pulmonis* infection, viral-bacterial cooperation in, 202
Mycotic infections, mixed, see Mixed mycotic infections
Myelin basic protein, in multiple sclerosis pathogenesis, 101
Myelin disorders
in multiple sclerosis, see Multiple sclerosis
viruses inducing, 103–107
Myelin oligodendrocyte glycoprotein, in multiple sclerosis pathogenesis, 101–102
Myelopathy, in human T-lymphotropic virus infection, 12, 79–80, 82, 84, 107, 112
NANB hepatitis virus infection, see Hepatitis C virus infection
Nasal turbinate, atrophy of, in atrophic rhinitis, 171–172, 171f, 179
*Neisseria gonorrhoeae*, in abscesses, 155, 156t, 161
*Neisseria meningitidis* infection, viral-bacterial cooperation in, 201, 203t, 204
Neonatal calves, bovine viral diarrhea virus infection of, 33, 35, 39–42
*Neospora caninum* infection, bovine viral diarrhea virus infection with, 41
Neuraminidase
in otitis media pathogenesis, 280
of swine influenza virus, 235–236
Neurologic disorders, in human immunodeficiency virus–human T-lymphotropic virus type 2 coinfection, 82–83
Neutrophils, dysfunction of
in otitis media, 274
in viral-bacterial cooperation, 205
Non–A, non–B hepatitis virus infection, see Hepatitis C virus infection
Normal flora
in abscesses, 153–154, 154f, 154t
antibiotic effects on, 339
*Candida* in, 335–338, 337t
in gastrointestinal tract, 153–155
in vagina, 128
“Norwalk-like” viruses, in gastroenteritis, 301, 303t, 304, 305t
Nose, bony atrophy in, see Atrophic rhinitis
Nosocomial infections, *Candida*, 358–361, 361f
NS3 protein, of bovine viral diarrhea virus, 36–37
Nucleoprotein, of measles virus, 378–379, 378f
Oligodendrocytes, dystrophy of, in multiple sclerosis, 100–101, 114
Onychomycosis, mixed species in, 346
Opportunistic infections
in HIV–HTLV-2 coinfection, 83
in HIV infection, 391–396
in measles virus infection, 379–380, 383
Oral cavity
*Candida*-bacterial population in
adhesion of, 363–364
biofilm formation in, 366–368, 366f
colonization of, 362–363, 362f
control of, 368–369
host environmental effects on, 369–370, 369f
infections with, 359–361, 361f, Color Plate 6
mixed community development in, 365–366, 364f, 365f
*Candida* in, 336–338, 337t, 340, 341, 351–352
organisms in
abscesses, 154t, 155, 156t–157t
continuous-culture chemostat system for, 22–25, 23f, 24t
periodontal diseases of, see Periodontal diseases
Oral hygiene
for Candida-bacterial biofilm control, 368
for periodontal disease control, 145, 317
Oseltamivir, for otitis media, 284
Osteoblasts and osteoclasts, dysregulation of, in
atrophic rhinitis, 170–172, 171f, 183–185
Otitis media, 259–298
animal models for, 263–266, 264f, 265f
antibiotic resistance in, 282
epidemiology of, 259
etiology of, 260–263, 262f
pathogenesis of, 266–281
antibiotic failure, 271–274, 272t
bacterial adherence and/or colonization, 266,
267f, 268
bacterial effects, 280–281
biofilm persistence, 281, 283, 406, Color Plate
3, Color Plate 4
Eustachian tube damage, 269–271, 269f, 270f,
272f
host defense defects, 274–275
treatment of, 283
viral effects, 266–280
recurrence of
cytokines in, 274
treatment of, 283
risk factors for, 260
treatment of, 259–260, 282–288, 284t, 285t,
286f–287f
antibiotics in, 282–283
antinflammatory agents in, 283
antiviral measures in, 283–285, 284t, 285t
bacterial vaccines in, 285, 286f–287f, 288
surgical, 283
viral effects on, 271–274, 272t
vaccination for, 283–285, 284t, 285t, 286f–287f,
288
after viral infections, timing of, 271, 272f
Oxygen concentrations, in anaerobic-aerobic
combinations, 164–166
P (phosphoprotein), of measles virus, 378–379,
378f
p53 protein, disruption of, in adult T-cell
leukemia/lymphoma pathogenesis, 78–79
Papillomatous digital dermatitis, 403
Papillon-Lefèvre syndrome, 321, 322t
Parainfluenza virus (human)
infection with, viral-bacterial cooperation in,
202
in otitis media, 261, 262f
Parainfluenza virus 3 (bovine)
in bovine respiratory complex, 216–217
infection with, bovine viral diarrhea virus
infection with, 41
Paramyxovirus (porcine), in porcine respiratory
disease complex, 242
Pasteurella multocida
in atrophic rhinitis, see Atrophic rhinitis
in bovine respiratory disease complex, 221
in porcine respiratory disease complex, 233, 233t,
235, 238, 240–241, 244–246, 248–249, 405
Pasteurellaceae, in bovine respiratory disease complex,
214, 220–221
Pasteurellosis, pneumonic, see Bovine respiratory
disease complex
PCR
for biofilm analysis, in otitis media, 281
for herpesvirus detection, 320
PCV2, see Porcine circovirus type 2
Pellicle, acquired, in dental plaque development,
138
Penicillin, for otitis media, 282
Peptococcus, in vagina, 338t
Peptostreptococcus
in abscesses, 155, 157t, 158, 163, 164t
in bacterial vaginosis, 131–133
dental implant colonization by, 360
in periodontal disease, 139, 142
Candida interactions with, 360
herpesvirus interactions with, 318
Periodontal diseases, 137–152, 317–331
Candida-bacteria interactions in, 360
chronic vs. aggressive, 137–138, Color Plate 1
classification of, 318
dental plaque development and, 138–139
description of, 317–318
herpesvirus-bacterium interactions in, 320–328
evidence for, 326–328
host response in, 325–326, 326f
in immunosuppression, 322–323, 322t
in juvenile disease, 320–321, 320t–322t
organisms in, 317
pathogenic mechanisms in, 324–325
organism culture in, continuous-culture chemostat
system for, 22–25, 23f, 24t
pathogens in, 317–318, see also Periodontal
diseases, herpesvirus-bacterium interactions in
adherence of, 139–140
in biofilm, 138–139
colonization by, 139–140
damage from, 142
detection of, 405
growth of, 139–140
in host defense interference, 140–141
host response to, 143–144
number of species, 138
tissue penetration and invasion by, 141–142
reversibility of, 317–318
risk factors for, 144–145, 405
subgingival pockets in, 140, 318
treatment of, 145–146
Pertactin, of Bordetella bronchiseptica, 176
Phagocytosis
in abscesses, 158–159, 164
interference with
in bovine respiratory disease complex, 222
INDEX

423

in HIV infection, 392
in viral-bacterial cooperation, 205
Phenotypic heterogeneity, in mixed fungal infections, 348, 350–352, 350f, 351f
Phosphoprotein, of measles virus, 378–379, 378f
Physiologic abnormalities, polymicrobial diseases in, 8–9
Picornaviruses
in gastroenteritis, 301
hepatitis A virus as, 52
PIE, see Postinfectious encephalomyelitis
Piedra, white, mixed fungal-bacterial causes of, 346
Pigs
atrophic rhinitis in, 169–197
Pili, of abscess-forming organisms, 160–161, 160f
Plaque
atherosclerotic, microorganisms in, 404
dental
formation of, 362–364
in periodontal disease, 137–139, 143, 145, Color Plate 1
in multiple sclerosis, 100, 101
Pleconaril, for otitis media, 284
Pneumococci, see Streptococcus pneumoniae
Pneumocystis carinii
infection with, in HIV infection, 392–393
in mixed infections, 346
Pneumonia
in bovine viral diarrhea virus infection, 40–41
in influenza epidemic of 1918, 201
Pneumocystis carinii, in HIV infection, 392–393
in porcine respiratory disease complex, 231–258
Pneumonic pasteurellosis, see Bovine respiratory disease complex
Poliovirus, in gastroenteritis, in vitro studies of, 309–310
Polymicrobial diseases, 6t
abscesses, 153–168
atrophic rhinitis, 169–197
bacterial vaginosis, 127–135
periodontal diseases, 137–152
Polymicrobial diseases, see also specific diseases and organisms
animal models for, 7–8
in animals, 5t
definition of, 403
detection of, 404–405
etiology of, 4, 5t–7t, 7, 404–405
fungal, 7t
in immunosuppression, 7t
mixed viral and bacterial, 6t
parasitic, 7t
polybacterial, see Polybacterial diseases
polyviral, see Polyviral diseases
historical perspective of, 4
new, 403–404
pathogenesis of, 8–12, 405–407
prevention of, 407
risk factors for, 405
synonyms for, 3
Polysaccharide capsule, in abscesses, 158–162, 160f, 162f
Polyserositis, in Haemophilus parasuis infection, 241–242
Polyviral diseases, 6t
bovine viral diarrhea virus, 33–50
hepatotropic viruses, 51–73
multiple sclerosis, 99–124
retroviruses, 75–97
Porcine circovirus type 2, in porcine respiratory disease complex, 233, 233t, 238–239, 248
Porcine coronavirus, in gastroenteritis, 306–307
Porcine cytomegalovirus, in porcine respiratory disease complex, 242
Porcine parvovirus, in porcine respiratory disease complex, 248
Porcine respiratory coronavirus bacterial interactions of, 220
in porcine respiratory disease complex, 237, 244–245, 247–248
Porcine respiratory disease complex, 231–258
definition of, 232
diagnosis of, 250
emerging pathogens in, 232
epidemiology of, 231
etiologic agents in, 233–243, 233t
Actinobacillus pleuropneumoniae, 233, 233t, 238, 239, 241, 244, 245, 248–249
Chlamydia, 233
Haemophilus parasuis, 235, 238, 240–242, 244, 246, 249
porcine circovirus type 2, 233, 233t, 238–239, 248
porcine parvovirus, 248
porcine reproductive and respiratory syndrome virus, 233–238, 233t, 240, 242, 245–247
porcine respiratory coronavirus, 237, 244–245, 247–248
pseudorabies virus, 237–238, 242, 244
Salmonella choleraesuis, 233, 233t, 245–246
Streptococcus suis, 233, 233t, 235, 238, 240, 242, 244–246, 249
Porcine respiratory disease complex (continued)
swine influenza virus, 233, 233t, 235–237, 245, 247–248
transmissible gastroenteritis virus, 238, 237
multifactorial nature of, 231–232, 232f
pathogenesis of, 243–250, 243f, 406
in polymicrobial bacterial disease, 248–250
in polymicrobial viral disease, 247–248
in viral-bacterial involvement, 244–247
prevention of, 232, 251
treatment of, 250–251
vaccination for, 251

Porphyromonas
in abscesses, 155, 157t, 158–161, 163–164, 166
in periodontal disease, herpesvirus interactions
with, 317, 318, 320–321, 320t, 323–325, 323t

Porphyromonas gingivalis
in biofilm formation, 363
Candida coaggregation with, 365, 365f
in periodontal disease, 139–142, 144, 145, 360

Porphyromonas intermedia, in periodontal disease, 141–142, 144
Postinfectious encephalomyelitis, 105–106
Postweaning multisystemic wasting syndrome, 238–239, 403
Poult enteritis mortality syndrome, 403, 405
PPV, see Porcine parvovirus
PRCV, see Porcine respiratory coronavirus
Prednisolone, for otitis media, 283
Pregnancy, bacterial vaginosis in, 130, 133
Prevotella
in abscesses, 154, 155, 157t, 158–161, 163–164, 166
in bacterial vaginosis, 132, 133
dental implant colonization by, 360
in periodontal disease, 139
Candida with, 359
herpesvirus interactions with, 317, 318, 323, 323t
Probiotics, for Candida infections, 369
Progressive multifocal leukoencephalopathy, 106
Propionibacterium acnes, in abscesses, 157t
Prosthetic devices, Candida on, 358–361, 361f, 369
Proteases
in bovine respiratory disease complex, 222
in influenza virus hemagglutinin cleavage, 206–207
in periodontal disease, 142
Protein A, staphylococcal, in viral-bacterial cooperation, 204
Proteus, in abscesses, 156t, 159, 163, 163t, 164
PRRSV, see Porcine reproductive and respiratory syndrome virus
PRV, see Pseudorabies virus

Pseudomonas aeruginosa
in abscesses, 156t, 161, 163, 163t, 165f, 166t
in biofilms, antibiotic resistance of, 407
infection with
in measles virus infection, 379
viral-bacterial cooperation in, 202, 204t
Pseudorabies virus, in porcine respiratory disease complex, 237–238, 242, 244
Pyrimethamine-sulfadiazine, for toxoplasmosis, 395
Random amplified polymorphic DNA technique, for Candida fingerprinting, 342
RANTES, in human immunodeficiency virus–human T-lymphotropic virus infections, 85–86
RAPD, see Random amplified polymorphic DNA technique
Regulators of complement activation proteins, in demyelination, 110–111
Reovirus infection, viral-bacterial cooperation in, 202
Reproductive infections, bovine viral diarrhea virus in, 41–42
Research, on polymicrobial diseases, 403–410
ettiologic agents, 404–405
new, 403–404
pathogenic mechanisms, 405–407
prophylaxis and treatment, 407
Resistance, antibiotic
in biofilms, 407
in otitis media, 282
Respiratory infections
abscess-forming organisms in, 160
atrophic rhinitis, 169–197
bovine viral diarrhea virus in, 39–41
otitis media resulting from, see Otitis media
porcine respiratory disease complex, 231–258
viral-bacterial cooperation in, 201–212
evidence of, 202–203
mechanisms of, 203–207, 203t, 204t
observations of natural disease in, 201–202
Respiratory syncytial virus (bovine), in bovine respiratory disease complex, 217–218
Respiratory syncytial virus (human), 217–218
infection with, viral-bacterial cooperation in, 202–205, 203t, 204t, 217–218
in otitis media, 260–261, 262f, 267f, 268, 271, 285
Restriction fragment length polymorphism analysis, of mixed fungal strains and substrains, 347
Retroviruses, see also Human immunodeficiency virus infection; Human T-lymphotropic virus infection
in multiple sclerosis pathogenesis, 112, 113
Rhinitis, atrophic, see Atrophic rhinitis
Rhinotracheitis, bovine, in bovine respiratory disease complex, 214–216
Rhinovirus, in otitis media, 261, 270–271
Rho kinase, in Pasteurella multocida toxin activation, 183
Ribavirin
for hepatotropic virus coinfections, 63–64
for measles, 383
Rimantadine, for otitis media, 283–284
Robbins device, for continuous culture, 25
Root planing, for periodontal disease, 145–146
Rotaviruses, in gastroenteritis, 300–301, 303, 305–306, 305t
animal models of, 306–308
in vitro studies of, 309–310
Rpd3 (deacetylase), in fungal phenotype switching, 351
RSV, see Respiratory syncytial virus
RTX toxin family, in periodontal diseases, 140
S
AB, see Similarity coefficient
Saliva, microbial colonization and, 362–363, 362f
Salmonella, in gastroenteritis, 300, 302t–305t, 303, 304
in vitro studies of, 308–309
Salmonella choleraesuis, in porcine respiratory disease complex, 233, 233t, 245–246
Salmonella enterica infection, bovine viral diarrhea virus infection with, 41
“Sapporo-like” viruses, in gastroenteritis, 301, 305t
Scaling, for periodontal disease, 145–146
Schnüffelkrankheit, see Atrophic rhinitis
Scopulariopsis brevicaulis, in mixed fungal infections, 346
Secretion systems, type III secretion, atrophy of, 180
Sensory polyneuropathy, in human immunodeficiency virus–human T-lymphotropic virus coinfection, 82
Seratia marcescens, in abscesses, 156t
Sexual activity
bacterial vaginosis and, 129–131, 130f, 133
HIV transmission in, 389
HTLV transmission in, 75–77
Sheep
adenovirus infections in, 219
gastroenteritis in, mixed viral-bacterial, 308
Shigella, in gastroenteritis, 300, 302–305t, 304, 306
in vitro studies of, 309–310
Shipping fever, see Bovine respiratory disease complex
SIDS, see Sudden infant death syndrome
Signaling lymphocytic activation molecule gene, in measles virus-induced immunosuppression, 382
Simian T-lymphotropic viruses, 77
Similarity coefficient, in Candida fingerprinting, 342–343, 342f, 343t, 344f, 345
SIV, see Swine influenza virus
Skin, Candida carriage on, 336–338, 337t
SLAM gene, see Signaling lymphocytic activation molecule gene
Smoking
bacterial vaginosis and, 405
periodontal disease and, 144, 360
Sniffing disease, see Atrophic rhinitis
Soluble immunosuppressive factor, measles virus-induced, 380–381
Spinocerebellar syndrome, in human immunodeficiency virus–human T-lymphotropic virus coinfection, 82
SSPE, see Subacute sclerosing panencephalitis
Staphylococci
colonization by, on voice prosthesis, 361
dental implant colonization by, 360
toxins of, in viral-bacterial cooperation, 206
on vascular catheters, 361
Staphylococcus aureus
in abscesses, 155, 156t, 161, 163, 163t, 165f, 166t
in cheilitis, Candida with, 359
infection with
measles virus infection, 379
viral-bacterial cooperation in, 201–203, 203t, 204t, 206–207
in otitis media, 264f
in periodontal disease, 360
Candida with, 359
in pneumonia, Candida with, 346
in prosthesis infections, 361
in stomatitis, Candida with, 359
on vascular catheters, 361
Staphylococcus epidermidis
Candida interactions with, 367
in vagina, 338t
Statherin, in biofilm formation, 362, 363
STLVs, see Simian T-lymphotropic viruses
Stomatitis, denture-related, 359, Color Plate 6
Streptococci
Candida interactions with, 367
in vagina, 338t
Streptococcus gordonii, Candida coadhesion with, 364f–366f, 365–366
Streptococcus pneumoniae
in abscesses, 163
infection with
measles virus infection, 379
viral-bacterial cooperation in, 201–203, 203t, 204t, 205, 219
Streptococcus pyogenes, group A (Streptococcus pyogenes), see Streptococcus pyogenes
group A (Streptococcus pyogenes), viral-bacterial cooperation in, 203t, 204
group B, viral-bacterial cooperation in, 202, 204, 204t
group D, in vagina, 338t
non-viridans, in bacterial vaginosis, 131–132
nonhemolytic non-group D, in vagina, 338, 338t
on oral cavity structures, 363
Streptococcus gordoni, Candida coadhesion with, 364f–366f, 365–366
Streptococcus pneumoniae
in abscesses, 163
infection with
measles virus infection, 379
viral-bacterial cooperation in, 201–203, 203t, 204t, 205, 219
Streptococcus pneumoniae (continued)
in otitis media, 260–261
in animal models, 263–265, 264f
pathogenic mechanisms and, 266, 268, 269f, 271, 273–274, 280–281
treatment of, 282
Streptococcus pyogenes (group A streptococcus)
in abscesses, 155, 156t, 161, 163, 165f
infection with
in measles virus infection, 379
viral-bacterial cooperation in, 203t, 204
Streptococcus suis, in porcine respiratory disease complex, 233, 233t, 235, 238, 240, 242, 244–246, 249
Streptomyces griseus infection, viral-bacterial cooperation in, 207
Stress, polymicrobial diseases in, 8–9, 405
Subacute sclerosing panencephalitis, 106
Sudden infant death syndrome, viral-bacterial cooperation in, 202–203, 206
Sulfonamides, for atrophic rhinitis, 172
Swine, see Pigs
Switching mechanisms, in mixed fungal infections, 348, 350–352, 350f, 351f
Synergism, in polymicrobial infection pathogenesis, 10–12, 405–406
abscesses, 163–166, 163t, 164t, 165f, 166t
of cytokines, 9–10
gastroenteritis, 307
porcine respiratory disease complex, 245
T lymphocytes
activation of, in herpesvirus infections, 319–320
bovine viral diarrhea virus infection of, 38–41
in demyelination
in multiple sclerosis, 101–102
virus-induced, 104–105
destruction of, in HIV infection, 12, 390–396
dysfunction of, in cytomegalovirus infections, 324–325
HTLV infection of, 76
infiltration of, in HIV–HTLV-2 coinfection, 81–82
measles virus interactions with, 380–383
response of, in bovine respiratory disease complex, 216
Tax protein
in adult T-cell leukemia/lymphoma pathogenesis, 78–79
in HIV–HTLV coinfections, 85
Teeth, supporting structure loss from, see Periodontal diseases
Tetracyclines
for atrophic rhinitis, 172–173
normal flora imbalance caused by, 339
Théler’s murine encephalomyelitis virus infection, demyelination in, 104–105
Toenail, onychomycosis of, mixed species in, 346
Tonsil, bovine viral diarrhea virus infection of, 245
Tooth instability and loss, in periodontal diseases, see Periodontal diseases
Toroviruses, in gastroenteritis, 301, 303, 305
Toxins
in atrophic rhinitis
Bordetella bronchiseptica, 176–180, 177f
Pasteurella multocida, 182–187
diphtheria, in viral-bacterial cooperation, 206
in gastroenteritis, 299–300
in periodontal diseases, 140–141
in porcine respiratory disease complex, 240–241
in sudden infant death syndrome, 206
Toxoplasma gondii infection, in human immunodeficiency virus infection, 393–395
Tracheal cytotoxin in atrophic rhinitis, 179–180, 186
in porcine respiratory disease complex, 250
Transmissible gastroenteritis virus, in porcine respiratory disease complex, 238, 237
Tremacama, for otitis media, 284
Treponema, in periodontal disease
Candida with, 359
herpesvirus interactions with, 318
Treponema denticola
Candida with, 360
herpesvirus interactions with, 317, 323, 323t
Trichomonas vaginalis, in vaginitis, Candida with, 346
Trichosporon, in mixed infections
bacterial, 346
fungal, 346
Trimethoprim-sulfamethoxazole for Pneumocystis carinii infection, 393
for toxoplasmosis, 395
Tropical spastic paraparesis, 12, 107, 112
HIV infection and, 79–80, 82, 84
Trypsin, in influenza virus hemagglutinin cleavage, 207
Tuberculosis, viral exacerbation of, 202
Tubes, organism colonization on, 361
Tumor necrosis factor alpha
in bovine respiratory disease complex, 220
in multiple sclerosis, 101–102
in otitis media, 274
in periodontal disease, 324
in polymicrobial infections, 9–10
in porcine respiratory disease complex, 244, 247–248
Tympanostomy tubes, for otitis media, 283
Type III secretion systems, atrophy of, 180
Ureaplasma, in bovine respiratory disease complex, 221–222
V protein, of measles virus, 379

Vaccination
for atrophic rhinitis, 173–174
for bovine respiratory disease complex, 213
for bovine viral diarrhea virus, 38
for hepatitis A virus, 52, 59
for hepatitis B virus, 52
for influenza virus, 284–285, 284t, 285t
for measles virus, 378, 383
for otitis media, 283–285, 284t–285t, 286f–287f, 288
for porcine respiratory disease complex, 251

Vagina, see also Bacterial vaginosis
Candida in, 336–338, 337t
with bacteria, 338–339, 338t, 339f
fingerprinting of, 343, 343t, 344f, 345
multiple species in, 340–341
phenotype switching of, 351, 351f
progesterone effects on, 358
recurrent infections with, 345–346, 348

Varicella-zoster virus, in multiple sclerosis
pathogenesis, 111–112

Veillonella, in abscesses, 157t
Vibrio, in gastroenteritis, 300, 302t, 303t, 305–306

Viral interference
in HBV-HCV coinfection, 54
in HBV-HCV-HDV coinfection, 57–58

Virulence factors
in abscesses, 158
in atrophic rhinitis, see Atrophic rhinitis, virulence factors in
in periodontal disease, 142
of Salmonella suis, 242

Viruses, see also specific viruses and diseases
in combination with bacteria, 4, 5t–7t, 7
bovine respiratory disease, 213–229
cooperation between, 201–212
gastrointestinal infections, 299–316
otitis media, 259–298
periodontal disease, 317–331
porcine respiratory disease complex, 231–258
in combination with other viruses, see Polyviral diseases
in immunosuppression, 7t, 377–400

Visceral leishmaniasis, in human immunodeficiency virus infection, 395–396

Vitamin A, for measles treatment, 383

Voice prosthesis, Candida-bacterial infection of, 360–361, 361f, 369

Western blot test, for human immunodeficiency virus, 391

White piedra, mixed fungal-bacterial causes of, 346

Xerostomia, dental plaque formation in, 362

Yersinia, in gastroenteritis, 300, 305t, 310

Zanamivir, for otitis media, 284

Zidovudine, for adult T-cell leukemia/lymphoma, 79